RESEARCH ARTICLE

Risk factors for lower extremity amputation in patients with diabetic foot ulcers: A metaanalysis

Chunmei Lin¹, Jinhao Liu²*, Hu Sun²

1 Department of Endocrinology and Metabolism, Fujian Medical University Xiamen Humanity Hospital, Xiamen, Fujian Province, People's Republic of China, 2 Department of Vascular Surgery, Zhongshan Hospital Affiliated to Xiamen University, Xiamen, Fujian Province, People's Republic of China

* hao3232011@hotmail.com

Abstract

Purpose

A considerable number of diabetic foot ulcer (DFU) patients require amputation every year, which worsens their quality of life, aggravates the social burden, and shortens their life expectancy. Considering these negative effects, it is important to explore the relative risk factors affecting amputation in DFU patients.

Methods

The PubMed, SCIE and Embase databases were comprehensively searched for prospective or retrospective studies published before October 31, 2019. All English language studies involving DFU patients were included, and RevMan 5.3 software was used to analyse the data.

Results

This meta-analysis includes 21 studies involving 6505 participants, including 2006 patients who required a lower limb amputation. The following variables were associated with an increased risk of amputation: male sex (odds ratios (OR) = 1.30, 95% confidence interval (CI) = $1.16 \sim 1.46$, P<0.00001), smoking history (OR = 1.19, 95% CI = $1.04 \sim 1.35$, P = 0.009), a history of foot ulcers (OR = 2.48, 95% CI = $2.00 \sim 3.07$, P<0.00001), osteomyelitis (OR = 3.70, 95% CI = $3.02 \sim 4.53$, P<0.00001), gangrene (OR = 10.90, 95% CI = $5.73 \sim 20.8$, P<0.00001), a lower body mass index (mean difference IV (MD) = -0.88, 95% CI = $-1.30 \sim -0.47$, P<0.0001), and a higher white blood cell count (MD = 2.42, 95% CI = $2.02 \sim 2.82$, P<0.00001). However, age (MD = 1.24, 95% CI = $-0.45 \sim 2.93$, P = 0.15), type of diabetes (OR = 0.96, 95% CI = $0.61 \sim 1.52$, P = 0.86), hypertension (OR = 1.19, 95% CI = $0.96 \sim 1.47$, P = 0.12), and HbA1c level (MD = 0.02, 95% CI = $-0.28 \sim 0.33$, P = 0.87) were not associated with amputation in patients with DFU.



G OPEN ACCESS

Citation: Lin C, Liu J, Sun H (2020) Risk factors for lower extremity amputation in patients with diabetic foot ulcers: A meta-analysis. PLoS ONE 15 (9): e0239236. <u>https://doi.org/10.1371/journal.</u> pone.0239236

Editor: Manal S. Fawzy, Suez Canal University Faculty of Medicine, EGYPT

Received: May 10, 2020

Accepted: September 1, 2020

Published: September 16, 2020

Copyright: © 2020 Lin et al. This is an open access article distributed under the terms of the <u>Creative</u> Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript and its Supporting Information files.

Funding: The authors received no specific funding for this work.

Competing interests: The authors have declared that no competing interests exist.

Conclusions

Our meta-analysis identified several risk factors for amputation in DFU patients, including the male sex, a smoking history, a history of foot ulcers, osteomyelitis, gangrene, a lower body mass index, and a higher white blood cell count. Once gangrene occurs, the risk of amputation rapidly increases.

Introduction

Diabetes mellitus, which is among the most common endocrine diseases, severely deteriorates patients' quality of life; even worse, this condition shortens their life expectancy. More than 415 million people worldwide suffer from diabetes. More seriously, the prevalence of diabetes is still rising, and it is expected that the number of people affected will surge to 640 million by 2040 [1]. Currently, up to 1/4 of diabetic patients can develop foot ulcers, and at least one-quarter of these ulcers do not heal, placing such patients at risk of amputation [2].

Diabetic foot ulcer (DFU) is the leading cause of hospitalization in diabetic patients and among the most common, severe and costly complications of diabetes mellitus, resulting in major medical, financial, and social consequences for the patients, their families and society in general [3]. Approximately 40% to 60% of nontraumatic lower limb amputations worldwide are caused by diabetic complications, and 80% of these amputations follow diabetic foot ulcer [4]. Previous studies have shown that amputations (including major and minor amputations) caused by diabetes have a high mortality rate with a 5-year survival rate of 41% to 48% [5, 6]. Even in patients with minor amputations, the 5-year survival rate is only 59% [5].

Knowledge of the risk factors for amputation can be helpful for patients newly diagnosed with DFU. Considering the above reasons, it is necessary to be able to identify the relative risk factors for lower extremity amputation (LEA) in patients with DFU that can be modified to avoid or delay the severe consequences. To address these issues, we performed a meta-analysis to assess the risk factors associated with LEA in DFU patients.

Methods

This meta-analysis was based on the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement [7].

Search strategy

The PubMed, Embase and Web of Science databases were used to conduct a systematic literature search for studies published through October 31, 2019. The following terms were used for DFU: "Diabetic Feet" OR "Diabetic Foot" OR "Foot Ulcer, Diabetic". The keywords used for the risk factors included "Predictive factors" OR "Predictive factor" OR "Risk Factors" OR "Risk Factor" OR "Population at Risk" OR "Predictors". The terms associated with amputation included "Amputation" OR "Limb loss". The three authors carried out an independent selection process and resolved their differences through discussion.

Inclusion and exclusion criteria

In this meta-analysis, the included studies had to meet the following criteria: (i) the articles were prospective or retrospective publications based on original data; (ii) the articles were published in the English language; (iii) all patients were diagnosed with DFU regardless of the

diabetes type; (iv) all patients were diagnosed with DFU with or without a history of amputation or ulcers; and (v) the demographics and clinical characteristics of the DFU patients were available for the data extraction. Studies meeting the following exclusion criteria were eliminated from this meta-analysis: (i) reviews, letters to the editor, commentaries and editorials, irretrievable articles, animal studies and other studies from which patient data could not be extracted; (ii) studies in which the full text was not written in the English language; and (iii) simple diabetic foot patients without ulcers or simple diabetic foot infection patients. Two independent authors screened all titles and abstracts to determine eligibility. The full texts were browsed when eligibility could not be determined by the abstracts, and any discrepancies were resolved through discussion. All studies identified by the search strategy were exported to Endnote X8 software.

Data extraction and quality assessment

Two authors extracted the relevant data from the included articles into a structured table. The first author, year of publication, country and region, research design, number of cases, incidence, potential risk factors and corresponding data were recorded independently. Two researchers evaluated the quality of the studies independently using the Newcastle–Ottawa Scale (NOS). The NOS was used to assess the risk of bias based on the following three major components: (i) "group selection" (up to 4 points); (ii) "comparability" (up to 2 points); and (iii) "assessment of outcome or exposure" (up to 3 points). The total NOS score of each study ranged from 0 to 9 [8], and the studies were considered high-quality studies if they scored equal to or greater than 5 [9].

Statistical analysis

The statistical analysis of the data was performed using RevMan 5.3 software. The results are presented as the mean difference IV (MD) or odds ratios (ORs) with a 95% confidence interval (CI), and a P-value<0.05 was considered statistically significant unless otherwise specified. In addition, heterogeneity was quantified using the Q test and I² statistics. When the heterogeneity test indicated no significant difference (P>0.1 and I²<50%), a fixed-effects model was applied; otherwise, a random-effects model was used. Begg's funnel plot test was used to assess possible publication bias. A trial sequential analysis (TSA) was used to determine whether the sample size is sufficient to obtain significant results.

Results

After systematically searching the databases, 978 studies were initially retrieved. After identifying items without content and studies published in non-English languages, 321 studies were excluded. Then, the titles and abstracts were carefully scanned, and 587 reviews, case reports, letters and irrelevant studies were excluded. The full texts of the remaining 70 articles were carefully evaluated, and 21 studies that met the inclusion and exclusion criteria were ultimately incorporated in this meta-analysis [10–30]. In total, 6505 patients were included in this metaanalysis, and amputation occurred in 2006 patients who were diagnosed with DFU. The basic characteristics of the included studies are summarized in Table 1. A flow chart of the selection process of the studies included in this meta-analysis is shown in Fig 1.

Sex

The data were analysed using a fixed-effects model (P = 0.20, $I^2 = 20\%$). The incidence of amputation was 32.81% in the male DFU patients and 28.08% in the female patients. The male

Author	Year	Study design	Country/Region	Sample size (LEA/total)	Rate %	Quality assessment	
Ugwu, E. [11]	gwu, E. [11] 2019		Nigeria	119/336	35.42	7	
Sayiner, Z. A. [<u>12</u>]	2019	retrospective	Turkey	143/400	35.75	6	
Jeyaraman, K. [13]	2019	retrospective	Australia	263/513	51.27	6	
Guo, Z. [<u>14</u>]	2019	retrospective	China	59/475	12.42	6	
Kim, S. Y. [<u>15</u>]	2019 retrospectiv		Korea 28/73		38.36	6	
Musa, I. R. [<u>16</u>]	a, I. R. [16] 2018 prospect		Saudi Arabia	33/82	40.24	7	
Jeong, E. G. [<u>17</u>]	ng, E. G. [17] 2018 ret		Korea 113/192		58.85	6	
Ferreira, L. [<u>18</u>]	[18] 2018 retrosp		Portugal	48/479	10.02	6	
Saleem, S. [<u>19</u>]	2017 prospecti		Pakistan	31/107	28.97	7	
Jeon, B. J. [<u>20</u>]	2017 retrospect		Korea	67/137	48.91	6	
Jiang, Y. [<u>21</u>]] 2015 retrospec		China	133/669	19.88	6	
Chuan, F. [22]	. [22] 2015 retrospect		China	62/364	17.03	6	
Blumberg, S. N. [<u>23</u>]	, S. N. [23] 2014 retrospect		USA	99/234	42.31	5	
Zubair, M. [<u>24</u>]	[24] 2012 prospective		India	46/162	28.40	7	
Sun, J. H. [<u>25</u>]	H. [25] 2012 retrospecti		China	338/789	42.84	6	
Li, X. [<u>26]</u>	ζ. [26] 2011 retrosp		China	112/520	21.54	6	
Aydin, K. [<u>27</u>]	K. [27] 2010 retrospective		Turkey	16/74	21.62	6	
Yesil, S. [<u>28]</u>	2009 retrospective		Turkey	213/574		6	
Al-Tawfiq, J. A. [<u>29]</u>	2009	prospective	Saudi Arabia	12/62	19.35	6	
Mehmood, K. [<u>30</u>]	2008	retrospective	Pakistan	17/116	14.66	6	
Gurlek, A. [31]	1998	retrospective	Turkey	54/147	36.73	6	

Table 1. Basic characteristics of the included studies.

https://doi.org/10.1371/journal.pone.0239236.t001

patients with DFU had a significantly higher incidence of amputation (OR = 1.30, 95% CI = $1.16 \sim 1.46, P < 0.00001$) (Fig 2A).

Smoking history

Smoking history is defined as past or present smoking. Many DFU patients have a history of smoking. Therefore, we evaluated the influence of smoking history on the amputation





Fig 1. Flow chart of the selection process in this meta-analysis.

https://doi.org/10.1371/journal.pone.0239236.g001

	Mal	е	Fema	ale		Odds Ratio			Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95	SCI Y	ear	M-H, Fixed, 95% Cl	
Sayiner, Z. A.	101	256	42	144	6.4%					
Ugwu, E.	67	185	52	151	7.2%			019	-	
Jeyaraman, K.	175	322	88	191	10.0%				-	
Kim, S. Y.	12	33	16	40	1.8%					
Guo, Z. Ferreira, L.	36	294 294	23	181 185	4.9% 3.5%					
Jeong, E. G.	72	120	41	72	4.1%					
Musa, I. R.	24	55	9	27	1.3%					
Saleem, S.	21	64	10	43	1.6%					
Jeon, B. J.	40	79	27	58	3.0%					
Chuan, F.	38	219	24	145	4.7%	1.06 [0.60, 1			-	
Jiang, Y.	95	435	38	201	8.0%					
Blumberg, S. N.	89	177	10	57	1.5%					
Zubair, M.	37	106	9	56	1.5%					
Sun, J. H.	190 72	438	148 40	351 193	18.4%				T	
Li, X. Aydin, K.	12	52	40	193	0.9%					
Al-Tawfig, J. A.	8	30	4	32	0.6%					
Yesil, S.	154	391	59	183	9.6%				+	
Mehmood, K.	14	70	3	36	0.6%					
Gurlek, A.	38	97	16	50	2.5%					
Total (95% CI)		4044			100.0%	1.30 [1.16, 1	.46]		•	
Total events	1327		679							
Heterogeneity: Chi ² =				I* = 20*	20				0.01 0.1 1 10	10
Test for overall effect	CZ= 4.43	(P < 0.1	00001)						Favours [Male] Favours [Female]	
	Smokin		Smoking			Odds Ratio			Odds Ratio	
						A-H, Fixed, 95% Cl			M-H, Fixed, 95% Cl	_
Kim, S. Y.	18	41	10	32	1.5%	1.72 [0.65, 4.54]	2019		M-H, Fixed, 95% Cl	
Kim, S. Y. Sayiner, Z. A.				32 262		A-H, Fixed, 95% Cl	2019		M-H, Fixed, 95% Cl	
Kim, S. Y. Sayiner, Z. A. Jeyaraman, K. Guo, Z.	18 65 154 23	41 138 282 237	10 78 109 36	32 262 231 235	1.5% 6.8% 12.9% 7.8%	A.H, Fixed, 95% CI 1.72 [0.65, 4.54] 2.10 [1.37, 3.22] 1.35 [0.95, 1.91] 0.59 [0.34, 1.04]	2019 2019 2019 2019 2019		M.H, Fixed, 95% CI	
Kim, S. Y. Sayiner, Z. A. Jeyaraman, K. Guo, Z. Musa, I. R.	18 65 154 23 6	41 138 282 237 10	10 78 109 36 27	32 262 231 235 72	1.5% 6.8% 12.9% 7.8% 0.6%	M.H. Fixed, 95% CI 1.72 [0.65, 4.54] 2.10 [1.37, 3.22] 1.35 [0.95, 1.91] 0.59 [0.34, 1.04] 2.50 [0.65, 9.66]	2019 2019 2019 2019 2019 2018		M.H, Fixed, 95% Cl	
Kim, S. Y. Sayiner, Z. A. Jeyaraman, K. Guo, Z. Musa, I. R. Jeong, E. G.	18 65 154 23 6 31	41 138 282 237 10 56	10 78 109 36 27 82	32 262 231 235 72 136	1.5% 6.8% 12.9% 7.8% 0.6% 5.1%	AH, Fixed, 95% Cl 1.72 [0.65, 4.54] 2.10 [1.37, 3.22] 1.35 [0.95, 1.91] 0.59 [0.34, 1.04] 2.50 [0.65, 9.66] 0.82 [0.44, 1.53]	2019 2019 2019 2019 2019 2018 2018		M-H, Fixed, 95% Cl	
Kim, S. Y. Sayiner, Z. A. Jeyaraman, K. Guo, Z. Musa, I. R. Jeong, E. G. Ferreira, L.	18 65 154 23 6 31 15	41 138 282 237 10 56 150	10 78 109 36 27 82 33	32 262 231 235 72 136 329	1.5% 6.8% 12.9% 7.8% 0.6% 5.1% 4.4%	AH, Fixed, 95% CI 1.72 [0.65, 4.54] 2.10 [1.37, 3.22] 1.35 [0.95, 1.91] 0.59 [0.34, 1.04] 2.50 [0.65, 9.66] 0.82 [0.44, 1.53] 1.00 [0.52, 1.90]	2019 2019 2019 2019 2019 2018 2018 2018 2018		M.H. Fixed, 95% Cl	
Kim, S. Y. Sayiner, Z. A. Jeyaraman, K. Guo, Z. Musa, I. R. Jeong, E. G. Ferreira, L. Chuan, F.	18 65 154 23 6 31	41 138 282 237 10 56	10 78 109 36 27 82	32 262 231 235 72 136 329 248	1.5% 6.8% 12.9% 7.8% 0.6% 5.1% 4.4% 4.6%	A.H., Fixed, 95% Cl 1.72 [0.65, 4.54] 2.10 [1.37, 3.22] 1.35 [0.95, 1.91] 0.59 [0.34, 1.04] 2.50 [0.65, 9.66] 0.82 [0.44, 1.53] 1.00 [0.52, 1.90] 1.44 [0.82, 2.54]	2019 2019 2019 2019 2019 2018 2018 2018 2018 2018 2015		MH, Fixed, 95% CI	
Kim, S. Y. Sayiner, Z. A. Jeyaraman, K. Guo, Z. Musa, I. R. Jeong, E. G. Ferreira, L. Chuan, F. Jiang, Y.	18 85 154 23 6 31 15 24	41 138 282 237 10 56 150 116	10 78 109 36 27 82 33 38	32 262 231 235 72 136 329 248	1.5% 6.8% 12.9% 7.8% 0.6% 5.1% 4.4%	A.H., Fixed, 95% CI 1.72 (0.65, 4.54) 2.10 (1.37, 3.22) 1.35 (0.95, 1.91) 0.59 (0.34, 1.04) 2.50 (0.65, 9.66) 0.82 (0.44, 1.53) 1.00 (0.52, 1.90) 1.44 (0.82, 2.54) 1.03 (0.71, 1.51)	2019 2019 2019 2019 2019 2018 2018 2018 2018 2015 2015		MH, Fixed, 95% CI	
Kim, S. Y. Sayiner, Z. A. Jeyaraman, K. Guo, Z. Musa, I. R. Jeong, E. G. Ferreira, L. Chuan, F. Jiang, Y. Zubair, M. Sun, J. H.	18 65 154 23 6 31 15 24 62 73 63	41 138 282 237 10 56 150 116 302 103 146	10 78 109 36 27 82 33 38 71 43 275	32 262 231 235 72 136 329 248 355 59 643	1.5% 6.8% 12.9% 7.8% 0.6% 5.1% 4.4% 4.6% 12.3% 3.8% 13.7%	A.H. Fixed, 95% CI 1.72 (0.65, 4.54) 2.10 (1.37, 3.22) 1.35 (0.95, 1.91) 0.59 (0.34, 1.04) 2.50 (0.65, 9.86) 0.82 (0.44, 1.53) 1.00 (0.52, 1.90) 1.44 (0.82, 2.54) 1.03 (0.71, 1.51) 0.91 (0.44, 1.85) 1.02 (0.71, 1.46)	2019 2019 2019 2019 2019 2018 2018 2018 2018 2015 2015 2015 2012		MH, Fixed, 95% CI	
Kim, S. Y. Sayiner, Z. A. Jeyaraman, K. Guo, Z. Musa, I. R. Jeong, E. G. Ferreira, L. Chuan, F. Jiang, Y. Zubair, M. Sun, J. H. U, X.	18 65 154 23 6 31 15 24 62 73 63 40	41 138 282 237 10 56 150 116 302 103 146 181	10 78 109 36 27 82 33 38 71 43 275 72	32 262 231 235 72 136 329 248 355 59 643 339	1.5% 6.8% 12.9% 7.8% 0.6% 5.1% 4.4% 4.6% 12.3% 3.8% 13.7% 9.3%	<u>A.H. Fixed, 95% CI</u> 1.72 [0.65, 4.54] 2.10 [1.37, 3.22] 1.35 [0.95, 1.91] 0.59 [0.34, 1.04] 2.50 [0.65, 9.66] 0.82 [0.44, 1.53] 1.00 [0.52, 1.90] 1.44 [0.82, 2.54] 1.03 [0.71, 1.51] 0.91 [0.44, 1.85] 1.02 [0.71, 1.46] 1.05 [0.68, 1.63]	2019 2019 2019 2019 2018 2018 2018 2018 2018 2018 2015 2015 2015 2012 2012 2012		MH, Fixed, 95% CI	
Kim, S. Y. Sayiner, Z. A. Jeyaraman, K. Guo, Z. Musa, I. R. Jeong, E. G. Ferreira, L. Chuan, F. Jiang, Y. Zubair, M. Sun, J. H. Li, X. Aydin, K.	18 65 154 23 6 31 15 24 62 73 63 40 5	41 138 282 237 10 56 150 116 302 103 146 181 20	10 78 109 36 27 82 33 38 71 43 275 72 11	32 262 231 235 72 136 329 248 355 59 643 339 54	1.5% 6.8% 12.9% 7.8% 0.6% 5.1% 4.4% 4.6% 12.3% 3.8% 13.7% 9.3% 1.1%	AH, Fixed, 95% CI 1.72 (0.65, 4.54) 2.10 [1.37, 3.22] 1.35 (0.95, 1.91) 0.59 (0.34, 1.04) 0.52 (0.65, 9.66) 0.65, 9.66) 0.62 (0.44, 1.53) 1.00 (0.52, 1.90) 1.44 (0.82, 2.54) 1.03 (0.71, 1.51) 0.91 (0.44, 1.85) 1.02 (0.71, 1.46) 1.05 (0.68, 1.63) 1.03 (0.73, 9.437)	2019 2019 2019 2019 2018 2018 2018 2018 2018 2018 2015 2015 2015 2012 2012 2012 2012 2011 2010		MH, Fixed, 95% CI	
Kim, S. Y. Sayiner, Z. A. Jeyaraman, K. Guo, Z. Musa, I. R. Jeong, E. G. Ferreira, L. Chuan, F. Jiang, Y. Zubair, M. Sun, J. H. Li, X. Aydin, K. Yesil, S.	18 65 154 23 6 31 15 24 62 73 63 40 5 97	41 138 282 237 10 56 150 116 302 103 146 181 20 235	10 78 109 36 27 82 33 38 71 43 275 72 11 116	32 262 231 235 72 136 329 248 355 59 643 339 54 339	1.5% 6.8% 12.9% 7.8% 0.6% 5.1% 4.4% 12.3% 3.8% 13.7% 9.3% 1.1% 13.3%	AH, Fixed, 95% CI 1.72 (0.65, 4.54) 2.10 (1.37, 3.22) 1.35 (0.95, 1.91) 0.59 (0.34, 1.04) 2.50 (0.65, 9.86) 0.82 (0.44, 1.53) 1.00 (0.52, 1.90) 1.44 (0.82, 2.54) 1.03 (0.71, 1.51) 0.91 (0.44, 1.85) 0.91 (0.44, 1.85) 1.02 (0.77, 1.46) 1.05 (0.68, 1.63) 1.30 (0.39, 4.37) 1.35 (0.39, 1.90)	2019 2019 2019 2019 2019 2018 2018 2018 2018 2015 2015 2015 2012 2012 2012 2011 2010 2009		MH, Fixed, 95% CI	
Kim, S. Y. Sayiner, Z. A. Jeyaraman, K. Guo, Z. Musa, I. R. Jeong, E. G. Ferreira, L. Chuan, F. Jiang, Y. Zubair, M. Sun, J. H. Li, X. Aydin, K. Yesil, S.	18 65 154 23 6 31 15 24 62 73 63 40 5	41 138 282 237 10 56 150 116 302 103 146 181 20	10 78 109 36 27 82 33 38 71 43 275 72 11	32 262 231 235 72 136 329 248 355 59 643 339 54	1.5% 6.8% 12.9% 7.8% 0.6% 5.1% 4.4% 4.6% 12.3% 3.8% 13.7% 9.3% 1.1%	AH, Fixed, 95% CI 1.72 (0.65, 4.54) 2.10 [1.37, 3.22] 1.35 (0.95, 1.91) 0.59 (0.34, 1.04) 0.52 (0.65, 9.66) 0.65, 9.66) 0.62 (0.44, 1.53) 1.00 (0.52, 1.90) 1.44 (0.82, 2.54) 1.03 (0.71, 1.51) 0.91 (0.44, 1.85) 1.02 (0.71, 1.46) 1.05 (0.68, 1.63) 1.03 (0.73, 9.437)	2019 2019 2019 2019 2019 2018 2018 2018 2018 2015 2015 2015 2012 2012 2012 2011 2010 2009		MH, Fixed, 95% CI	
Kim, S. Y. Sayiner, Z. A. Jeyaraman, K. Guo, Z. Musa, I. R. Jeong, E. G. Ferreira, L. Chuan, F. Jiang, Y. Zubair, M. Sun, J. H. J., X. Aydin, K. Yesil, S. Gurlek, A.	18 65 154 23 6 31 15 24 62 73 63 40 5 97 19	41 138 282 237 10 56 150 116 302 103 146 181 20 235	10 78 109 36 27 82 33 38 71 43 275 72 11 116 35	32 262 231 235 72 136 329 248 355 59 643 339 54 339	1.5% 6.8% 12.9% 7.8% 0.6% 5.1% 4.4% 4.6% 12.3% 3.8% 13.7% 9.3% 1.1% 13.3% 2.9%	AH, Fixed, 95% CI 1.72 (0.65, 4.54) 2.10 (1.37, 3.22) 1.35 (0.95, 1.91) 0.59 (0.34, 1.04) 2.50 (0.65, 9.86) 0.82 (0.44, 1.53) 1.00 (0.52, 1.90) 1.44 (0.82, 2.54) 1.03 (0.71, 1.51) 0.91 (0.44, 1.85) 0.91 (0.44, 1.85) 1.02 (0.77, 1.46) 1.05 (0.68, 1.63) 1.30 (0.39, 4.37) 1.35 (0.39, 1.90)	2019 2019 2019 2019 2018 2018 2018 2018 2018 2015 2015 2015 2012 2012 2011 2011 2010 2010		MH, Fixed, 95% CI	
Kim, S. Y. Sayner, Z. A. Jeyaraman, K. Ouo, Z. Musa, I. R. Jeong, E. G. Ferreira, L. Chuan, F. Jaong, Y. Zubair, M. Sun, J. H. Li, X. Aydin, K. Yesil, S. Gurlek, A. Total (95% CI) Total events	18 65 154 23 31 15 24 62 73 63 40 5 97 19 895	41 138 282 237 10 56 150 116 302 103 146 181 20 235 45 2062	10 78 109 36 27 82 33 38 71 43 275 72 11 116 35 : : : : : : : : : : : : : : : : : :	32 262 231 235 72 136 329 248 355 59 643 339 54 339 54 339 102 3436 1	1.5% 6.8% 12.9% 7.8% 0.6% 5.1% 4.4% 4.6% 12.3% 3.8% 13.7% 9.3% 1.1% 13.3% 2.9%	A.H., Fixed, 95% CI 1.72 (0.65, 4.54) 2.10 (1.37, 3.22) 1.35 (0.95, 1.81) 0.59 (0.34, 1.04) 2.50 (0.65, 9.66) 0.82 (0.44, 1.53) 1.00 (0.52, 1.90) 1.44 (0.82, 2.54) 1.02 (0.71, 1.51) 1.02 (0.71, 1.46) 1.03 (0.08, 4.37) 1.35 (0.96, 1.90) 1.44 (0.82, 8.7)	2019 2019 2019 2019 2018 2018 2018 2018 2018 2015 2015 2015 2012 2012 2011 2011 2010 2010		MH, Fixed, 95% CI	
Kim, S. Y. Ssynker, Z. A. Jeyaraman, K. Uoto, Z. Huosa, I. R. Jeong, E. G. Ferreira, L. Euroga, K. Sun, J. H. Zubair, M. Sun, J. H. Zubair, M. Sun, J. H. Vydin, K. Yedil, S. Surlek, A. Total (95% CI) Total events Heterogenetic, Chi ^a =	18 65 154 23 6 31 15 24 62 73 63 62 73 60 5 97 19 97 19 595 19.96, df=	41 138 282 237 10 56 150 116 302 103 146 181 20 235 45 2062 2062	10 78 109 36 27 82 33 38 71 43 275 72 11 116 35 20 1036 = 0.13); P	32 262 231 235 72 136 329 248 355 59 643 339 54 339 54 339 102 3436 1	1.5% 6.8% 12.9% 7.8% 0.6% 5.1% 4.4% 4.6% 12.3% 3.8% 13.7% 9.3% 1.1% 13.3% 2.9%	A.H., Fixed, 95% CI 1.72 (0.65, 4.54) 2.10 (1.37, 3.22) 1.35 (0.95, 1.81) 0.59 (0.34, 1.04) 2.50 (0.65, 9.66) 0.82 (0.44, 1.53) 1.00 (0.52, 1.90) 1.44 (0.82, 2.54) 1.02 (0.71, 1.51) 1.02 (0.71, 1.46) 1.03 (0.08, 4.37) 1.35 (0.96, 1.90) 1.44 (0.82, 8.7)	2019 2019 2019 2019 2018 2018 2018 2018 2018 2015 2015 2015 2012 2012 2011 2011 2010 2010	0.01		10
Kim, S. Y. Ssynker, Z. A. Jeyaraman, K. Uoto, Z. Huosa, I. R. Jeong, E. G. Ferreira, L. Euroga, K. Sun, J. H. Zubair, M. Sun, J. H. Zubair, M. Sun, J. H. Vydin, K. Yedil, S. Surlek, A. Total (95% CI) Total events Heterogenetic, Chi ^a =	18 65 154 23 6 31 15 24 62 73 63 62 73 60 5 97 19 97 19 595 19.96, df=	41 138 282 237 10 56 150 116 302 103 146 181 20 235 45 2062 2062	10 78 109 36 27 82 33 38 71 43 275 72 11 116 35 20 1036 = 0.13); P	32 262 231 235 72 136 329 248 355 59 643 339 54 339 54 339 102 3436 1	1.5% 6.8% 12.9% 7.8% 0.6% 5.1% 4.4% 4.6% 12.3% 3.8% 13.7% 9.3% 1.1% 13.3% 2.9%	A.H., Fixed, 95% CI 1.72 (0.65, 4.54) 2.10 (1.37, 3.22) 1.35 (0.95, 1.81) 0.59 (0.34, 1.04) 2.50 (0.65, 9.66) 0.82 (0.44, 1.53) 1.00 (0.52, 1.90) 1.44 (0.82, 2.54) 1.02 (0.71, 1.51) 1.02 (0.71, 1.46) 1.03 (0.08, 4.37) 1.35 (0.96, 1.90) 1.44 (0.82, 8.7)	2019 2019 2019 2019 2018 2018 2018 2018 2018 2015 2015 2015 2012 2012 2011 2011 2010 2010	0.01		11
Kim, S. Y. Sayiner, Z. A. Jeyaraman, K. Uoya, Z. Musa, I. R. Jeong, E. G. Ferreira, L. Chuan, F. Jang, Y. Zubair, M. Sun, J. H. Zubair, M. Sun, J. H. Kaydin, K. Yesil, S. Gurlek, A. Total (95% CI) Total sevents Heterogenetik, Chi ^a =	18 65 154 23 6 31 15 24 62 73 63 62 73 60 5 97 19 97 19 595 19.96, df=	41 138 282 237 10 56 150 116 302 103 146 181 20 235 45 2062 2062	10 78 109 36 27 82 33 38 71 43 275 72 11 116 35 20 1036 = 0.13); P	32 262 231 235 72 136 329 248 355 59 643 339 54 339 54 339 102 3436 1	1.5% 6.8% 12.9% 7.8% 0.6% 5.1% 4.4% 4.6% 12.3% 3.8% 13.7% 9.3% 1.1% 13.3% 2.9%	A.H., Fixed, 95% CI 1.72 (0.65, 4.54) 2.10 (1.37, 3.22) 1.35 (0.95, 1.81) 0.59 (0.34, 1.04) 2.50 (0.65, 9.66) 0.82 (0.44, 1.53) 1.00 (0.52, 1.90) 1.44 (0.82, 2.54) 1.02 (0.71, 1.51) 1.02 (0.71, 1.46) 1.03 (0.08, 4.37) 1.35 (0.96, 1.90) 1.44 (0.82, 8.7)	2019 2019 2019 2019 2018 2018 2018 2018 2018 2015 2015 2015 2012 2012 2011 2011 2010 2010	L.01		11
Kim, S. Y. Swinter, Z. A. Jeyaraman, K. Uoto, Z. Huosa, I. R. Jeong, E. G. Ferreira, L. Euroga, K. Sund, H. Sund, H. Sund, H. Sund, H. Sund, H. Sund, K. Yourke, A. Total (95% CI) Total events Heterogenetic, Chi ^a =	18 65 154 23 6 31 15 24 62 73 63 62 73 60 5 97 19 97 19 595 19.96, df=	41 138 282 237 10 56 150 116 302 103 146 181 20 235 45 2062 2062	10 78 109 36 27 82 33 38 71 43 275 72 11 116 35 20 1036 = 0.13); P	32 262 231 235 72 136 329 248 355 59 643 339 54 339 54 339 102 3436 1	1.5% 6.8% 12.9% 7.8% 0.6% 5.1% 4.4% 4.6% 12.3% 3.8% 13.7% 9.3% 1.1% 13.3% 2.9%	A.H., Fixed, 95% CI 1.72 (0.65, 4.54) 2.10 (1.37, 3.22) 1.35 (0.95, 1.81) 0.59 (0.34, 1.04) 2.50 (0.65, 9.66) 0.82 (0.44, 1.53) 1.00 (0.52, 1.90) 1.44 (0.82, 2.54) 1.02 (0.71, 1.51) 1.02 (0.71, 1.46) 1.03 (0.08, 4.37) 1.35 (0.96, 1.90) 1.44 (0.82, 8.7)	2019 2019 2019 2019 2018 2018 2018 2018 2018 2015 2015 2015 2012 2012 2011 2011 2010 2010	0.01		11
dim, S. Y. Sayiner, Z. A. Jeyaraman, K. Jeong, E. G. Ferreira, I. R. Jeong, F. G. Ferreira, K. Sun, J. H. Sun, J. H. Sun, J. H. J. X. Wain, K. Yourk, A. Fotal (95% CI) Total events febrogenety, Chi [#] =	18 65 154 23 6 31 15 24 62 73 63 62 73 60 5 97 19 97 19 595 19.96, df=	41 138 282 237 10 56 150 116 302 103 146 181 20 235 45 2062 2062	10 78 109 36 27 82 33 38 71 43 275 72 11 116 35 20 1036 = 0.13); P	32 262 231 235 72 136 329 248 355 59 643 339 54 339 54 339 102 3436 1	1.5% 6.8% 12.9% 7.8% 0.6% 5.1% 4.4% 4.6% 12.3% 3.8% 13.7% 9.3% 1.1% 13.3% 2.9%	A.H., Fixed, 95% CI 1.72 (0.65, 4.54) 2.10 (1.37, 3.22) 1.35 (0.95, 1.81) 0.59 (0.34, 1.04) 2.50 (0.65, 9.66) 0.82 (0.44, 1.53) 1.00 (0.52, 1.90) 1.44 (0.82, 2.54) 1.02 (0.71, 1.51) 1.02 (0.71, 1.46) 1.03 (0.08, 4.37) 1.35 (0.96, 1.90) 1.44 (0.82, 8.7)	2019 2019 2019 2019 2018 2018 2018 2018 2018 2015 2015 2015 2012 2012 2011 2011 2010 2010	L.01		1
Krim, S. Y. Swyner, Z. A. Jeyaraman, K. Quo, Z. Mutsa, I. R. Jeong, E. G. Ferreira, L. Chuan, F. Jiang, Y. Zubair, M. Sun, J. H. U.X. X. Wath, K. Krestl, S. Jouriek, A. Total (95% CI) Total sevents Heterogeneity, Chi ^p = Test for overall effect.	18 65 154 23 6 31 15 24 62 73 63 5 97 19 597 19 595 19.96,df= Z = 2.61 (F	41 138 282 237 10 56 150 116 103 120 130 146 181 20 235 45 2062 14 (P: P=0.00	10 78 109 36 27 82 33 38 71 43 275 72 11 116 35 20 5 1036 = 0.13); ² 19)	32 262 231 72 136 329 54 339 54 339 102 3436 1 = 30%	1.5% 6.8% 12.9% 7.8% 0.6% 4.4% 4.6% 12.3% 13.7% 9.3% 13.7% 9.3% 13.3% 2.9%	H4, Freed, 95% Cf 172 (105, 44) 173 (105, 44) 135 (105, 103) 159 (103, 103) 159 (103, 103) 159 (103, 103) 159 (103, 103) 159 (103, 103) 150 (103, 103) 140 (105, 103	2019 2019 2019 2019 2019 2019 2018 2018 2018 2018 2018 2018 2015 2015 2015 2015 2012 2012 2012 2011 2011 2010 2009 1998	0.01	0.1 Favours [Smoking-]	10
Krim, S. Y. Ssynker, Z. A. Jeyaraman, K. Quo, Z. Musa, I. R. Jeong, E. G. Ferreira, L. Chuan, F. Jiang, Y. Zubair, M. Sun, J. H. Ly, X. Avdin, K. Yesil, S. Gurlek, A. Total (96% CI) Total events Heterogeneity: Chi# = Test for overall effect	18 65 154 23 6 31 15 24 63 40 5 97 19 97 19 895 19.96, df = Z = 2.61 (F	41 138 282 237 10 56 150 116 302 103 146 181 20 235 45 2062 14 (P · - = 0.00 - = 0.00	10 78 109 36 27 82 33 38 71 43 275 72 11 116 35 ; 1036 = 0.13); P	32 262 231 235 72 136 329 248 355 59 54 339 54 339 54 339 54 339 54 339 54 = 30%	1.5% 6.8% 12.9% 7.8% 0.6% 5.1% 4.4% 4.6% 12.3% 13.7% 9.3% 13.7% 9.3% 13.3% 2.9% 00.0%	H4, Freed, 95: Cf 172 (105, 454) 172 (105, 454) 172 (105, 454) 153 (105, 101) 159 (103, 101) 159 (103, 101) 159 (103, 101) 159 (103, 101) 150 (103, 101) 144 (105, 106, 103) 145 (105, 106, 103) 144 (105, 106, 103) 145 (105, 106, 103) 145 (105, 106, 103) 146 (105, 106, 106, 103) 146 (105, 106, 106) 146 (105, 106) 146	2019 2019 2019 2019 2019 2019 2019 2018 2018 2018 2018 2015 2012 2018 2012 2017 2012 2012 2012 2011 2010 2009 1998	0.01	0.1 Favours [Smoking-]	10
Kim, S. Y. Sayiner, Z. A. Jeyaraman, K. Quo, Z. Mutsa, I. R. Jeong, E. G. Ferreira, L. Chuan, F. Jiang, Y. Zubari, M. Sun, J. H. Aydin, K. Yotal (95% CI) Total ergenetic, Chi ⁹ = Test for overall effect Total ergenetic, Chi ⁹ = Test for overall effect Temperature, C. Market, Schotcop, I Internet, C. Sayiner, Z. A.	18 85 154 23 6 31 15 24 62 73 63 5 97 19 695 19.96, df= Z = 2.61 (f) which previde turcer Previde turcer Previde	41 138 282 237 10 56 150 150 116 302 103 146 181 20 235 45 2062 214 (P = 2 205 205 205 205 205 205 205 20	10 78 109 36 27 33 38 71 43 275 72 11 116 35 275 72 11 35 20 5 72 11 1036 = 0.13); P	32 262 231 235 72 235 72 235 59 643 339 54 339 102 3436 1 = 30% revious- Total 285 205 205 205 205 205 205 205 20	1.5% 6.8% 7.8% 7.8% 0.6% 5.1% 4.4% 4.6% 3.8% 13.7% 13.3% 13.7% 9.3% 1.1% 13.3% 00.0%	H4 Freed .95: Cf 172 (165, 44) 172 (165, 44) 173 (165, 44) 153 (195, 191) 159 (191, 191) 159 (191, 191) 159 (191, 191) 159 (191, 191) 150 (191, 191) 144 (192, 254) 150 (194, 195) 150 (191, 191) 144 (192, 254) 150 (194, 195) 140 (198, 193) 144 (195, 196, 193) 144 (195, 196, 193) 144 (195, 254) 150 (194, 195) 140 (194, 194) 140 (2019 2019 2019 2019 2019 2019 2019 2019	6.01	0.1 Favours [Smoking-]	10
Kim, S. Y. Sayiner, Z. A. Jeyaraman, K. Quo, Z. Musa, I. R. Jeong, E. G. Ferreira, L. Chuan, F. Jiang, Y. Zubair, M. Sun, J. H. Li, X. Vesil, S. Gurlek, A. Total (99% CI) Total events K. Fost for overall effect. I Statem, S. Sater, S.	18 85 154 23 6 31 15 24 62 73 83 63 40 5 97 19.96, df = Z = 2.61 (f Utcer Prev4o Verest 177 73 52	41 138 282 237 10 56 150 116 302 103 146 181 200 235 2062 245 2062 245 2062 245 205 135 143	10 78 109 36 27 82 33 38 275 71 43 275 72 11 116 35 5 5 1036 6 0.13); P 99)	32 262 231 235 72 235 72 235 59 643 339 102 248 339 102 3436 1 233 406 1 218 218 248 248 248 248 248 248 248 24	1.5% 6.8% 7.8% 0.6% 4.4% 4.6% 3.8% 3.3% 1.1% 3.3% 2.9% 00.0%	LH, Freed, 95: Cl 172 (105, 44) 172 (105, 44) 173 (105, 107, 3.22) 173 (105, 101, 101, 102, 102, 102, 102, 102, 102	2019 2019 2019 2019 2019 2019 2019 2019	6.01	0.1 Favours [Smoking-]	10
Kim, S. Y. Sayiner, Z. A. Jeyaraman, K. Quo, Z. Musa, I. R. Jeong, E. G. Ferreira, L. Chuan, F. Julang, Y. Zubart, M. U.X. J. Maydin, K. Yotal, S. Gurlek, A. Total (95% CI) Total events Heterogenetic, Chi ² = Test for overall effect. Total space (Chi Programa, K. Sakert, S. Sakert, S. Sakert, S. Sakert, S. Sakert, S.	18 85 154 23 6 31 15 24 62 73 83 63 40 5 97 19 695 19.96, df = Z = 2.61 (f versts, 73 52 10 59 59	41 138 282 237 10 56 150 116 302 205 45 2062 245 205 135 143 45 143 45 143 143 45 143 143 143 143 143 143 143 143	10 78 109 36 27 72 275 72 275 72 275 72 275 72 275 72 275 72 21036 35 35 35 35 35 35 99 90	32 262 231 235 72 136 329 248 355 54 339 102 3436 1 = 30% revious- Total 218 226 219 218 247 248 248 248 248 248 248 248 248	15% 6.8% 6.8% 0.6% 5.1% 4.4% 12.3% 3.8% 9.3% 1.1% 9.3% 1.1% 2.9% 00.0%	H4 Freed 95% CI 172 (105, 454) 172 (105, 454) 172 (105, 454) 153 (105, 101) 159 (103, 101) 159 (103, 101) 159 (103, 101) 159 (103, 101) 150 (103, 101) 144 (105, 106, 103) 144 (105, 105, 103) 144 (105, 103) 14	2019 2019 2019 2019 2019 2019 2019 2019	0.01	0.1 Favours [Smoking-]	10
Kim, S. Y. Sayiner, Z. A. Jeyaraman, K. Quo, Z. Musa, I. R. Jeong, E. G. Ferreira, L. Chuan, F. Julang, Y. Zubart, M. U.X. J. Maydin, K. Yotal, S. Gurlek, A. Total (95% CI) Total events Heterogenetic, Chi ² = Test for overall effect. Total space (Chi Programa, K. Sakert, S. Sakert, S. Sakert, S. Sakert, S. Sakert, S.	18 85 154 23 6 31 15 24 62 73 63 5 5 5 5 5 19.96, df= Z = 2.61 (f) 19.96, df= Z = 2.61 (f) 19.96, df= 17.96, df= 17.96, df= 17.97, df= 17.96, df= 17.97, df= 17.	41 138 282 237 10 56 150 150 150 150 163 203 205 205 205 205 135 143 45	10 78 109 36 27 82 33 38 275 572 11 11 116 0.13); P 500 000 tulcer Pr 1036 0.13); P 500 000 tulcer Pr 1999	32 262 231 235 72 235 72 235 59 643 339 102 448 54 339 102 448 54 339 102 448 54 339 102 54 339 102 54 339 102 54 339 102 54 102 54 102 54 102 54 102 54 102 54 102 54 102 54 102 54 102 54 102 54 102 54 102 102 102 102 102 102 102 102	15% 6.8% 6.8% 0.6% 5.1% 4.4% 12.3% 3.8% 9.3% 1.1% 9.3% 1.1% 2.9% 00.0%	H4, Freed, 95% Cf 17 (2) 165, 445 210 (137, 322) 15 (2) 15, 107, 322 15 (2) 15, 107, 107, 107, 107, 107, 107, 107, 107	2019 2019 2019 2019 2019 2019 2019 2019	0.01	0.1 Favours [Smoking-]	10
	$\begin{array}{c} 18 \\ 85\\ 154\\ 23\\ 31\\ 154\\ 24\\ 62\\ 24\\ 62\\ 24\\ 80\\ 57\\ 19\\ 95\\ 19\\ 96\\ 57\\ 19\\ 95\\ 19\\ 24\\ 17\\ 73\\ 52\\ 10\\ 52\\ 24\\ 24\\ 24\\ 24\\ 24\\ 24\\ 24\\ 24\\ 24\\ 2$	41 138 282 237 10 56 150 150 116 302 235 45 2062 245 205 135 143 45 143 45 143 143 143 143 143 143 143 143	10 78 109 36 27 82 33 38 71 43 35 72 27 11 116 35 6 0.13), P 99) 000 talcer Pr 200 74 6 8 6 7 74 72 74 72 74 74 8 74 74 74 74 74 74 75 75 75 75 75 75 75 75 75 75 75 75 75	32 262 262 231 235 72 235 59 54 339 54 339 54 339 54 339 54 339 54 339 54 339 54 339 54 339 54 339 54 339 54 329 54 339 54 339 54 329 54 218 218 218 218 218 218 218 218	15% 6.8% 6.8% 0.6% 5.1% 4.4% 12.3% 3.8% 9.3% 1.1% 9.3% 1.1% 2.9% 00.0%	H4 Freed 95% CI 172 (105, 454) 172 (105, 454) 172 (105, 454) 153 (105, 101) 159 (103, 101) 159 (103, 101) 159 (103, 101) 159 (103, 101) 150 (103, 101) 144 (105, 106, 103) 144 (105, 105, 103) 144 (105, 103) 14	2019 2019 2019 2019 2019 2019 2019 2019	0.01	0.1 Favours [Smoking-]	10
Kim, S. Y. Sayiner, Z. A. Jeyaraman, K. Quo, Z. Musa, I. R. Jeong, E. G. Ferreira, L. Chuan, F. Jiang, Y. Zubair, M. Sun, J. H. U.X. K. Kotal (95% CI) Total events Heterogeneity. Chi ^p = Test for overall effect C Foot Staty of Schoroop I Staty of Schoroop I	18 85 154 23 31 154 46 24 46 24 46 24 73 63 40 57 97 97 19 19 695 52 24 24 24 24 24 24 25 26 26 26 26 27 26 27 26 27 27 27 27 27 27 27 27 27 27	41 138 282 237 10 56 150 150 150 160 150 160 120 235 45 2062 14 (P: 205 135 145 14 (P: 205 135 135 135 135 135 135 146 181 202 207 207 100 116 181 202 205 205 180 180 180 205 205 205 205 205 205 205 20	10 78 109 36 82 33 38 275 72 11 116 35 275 1036 0 1036 0 1037 10 90 90 90 90 90 90 90 90 77 72 21 11 116 106 90 90 90 90 90 90 90 90 90 90 90 90 90	32 262 262 231 235 72 235 59 54 339 54 339 54 339 54 339 54 339 54 339 54 339 54 339 54 339 54 339 54 339 54 329 54 339 54 339 54 329 54 218 218 218 218 218 218 218 218	15% 6.8% 12% 7.8% 5.1% 4.4% 4.4% 4.4% 4.4% 4.4% 4.4% 4.4% 3.3% 9.3% 13.3% 2.9% 00.0%	H4 Freed. 955: Cf 172 (105, 444) 173 (105, 444) 153 (105, 103) 159 (103, 103) 159 (103, 103) 159 (103, 103) 159 (103, 103) 159 (103, 103) 150 (103, 103) 144 (103, 103) 144 (103, 103) 145 (103, 103) 145 (103, 103) 146 (103, 1	2019 2019 2019 2019 2019 2019 2019 2019	0.01	0.1 Favours [Smoking-]	10



incidence in DFU patients. A fixed-effects model was used because of the lower heterogeneity of the data (P = 0.13, $I^2 = 30\%$). Five papers were included in this analysis, and the results revealed that a smoking history was among the factors influencing the incidence of amputation in DFU patients (OR = 1.19, 95% CI = $1.04 \sim 1.35$, P = 0.009) (Fig 2B).

History of foot ulcers

Patients who previously suffered from foot ulcers were included in this meta-analysis. A fixedeffects model was applied to this data analysis (P = 0.25, $I^2 = 24\%$), and 6 studies reporting a history of foot ulcers were included. The analysis indicated that DFU patients with a previous history of ulceration are more prone to amputation (OR = 2.48, 95% CI = 2.00~3.07, P<0.00001) (Fig 2C).

Osteomyelitis

A fixed-effects model was used to analyse the data of the DFU patients with osteomyelitis (P = 0.17, $I^2 = 34\%$). In total, 7 studies that revealed the effect of osteomyelitis on the incidence of amputation in DFU patients were included in this analysis. The analysis clearly illustrates

A 40 245 372 155 47 344 68 4.4% 11.8% 25.3% 17.8% 4.2% 28.0% 8.4% 59 102 43 8 133 39 91 141 79 27 230 79 60 161 56 8 80 15 5.68 [3.38, 9.56] 3.43 [2.25, 5.23] 2.11 [1.22, 3.66] 2019 .31 4.52 [3.15, 6.50] 674 1277 3701302 4 531 100.0% 393 *= 0.17); I² = 34% 0.00001) 399 Favours В Odds Rati
 Total
 Weight

 158
 34.8%

 160
 31.0%

 64
 10.7%

 103
 23.5%
 2019 2014 2010 1998 5.95 [3.54, 9.42 [4.94, 28.00 [5.03, 5.95 [3.54, 10.00] 9.42 [4.94, 17.97] 28.00 [5.03, 155.97] 21.25 [8.47, 53.30] 94 57 178 74 10 44 25 42 8 18 36 306 485 100.0% 10.92 [5.73, 20.80] Total (95% CI) 195 93 *= 7.49, df = 3 (= 0.06): 12 = 60% 0.1 Jrs [gangrene+ Eavor С Mean Difference IV, Fixed, 95% CI LEA LEA Study or Suby Guo, Z. Jeong, E. G. Jeon, B. J. Chuan, F. Yesil, S. Mehmood, K.
 Mean Difference

 W. Fixed, 95% Cl
 Ye

 -0.47 [-1.51, 0.57]
 20

 -0.70 [-1.70, 0.30]
 20

 -1.30 [-2.73, 0.13]
 20

 -0.30 [-1.29, 0.69]
 20

 -1.50 [-2.21, -0.79]
 20
 SD Total Mea SD Total Weight
 Mean
 SD

 22.63
 3.79

 23.5
 3.1

 23.1
 3.1

 22.1
 3.7

 25.6
 3.7

 28.2
 3.1

 Mean
 SD

 23.1
 3.86

 24.2
 3.7

 24.4
 5.2

 22.4
 2.9

 27.1
 4.9

 28.4
 3
 416 79 70 254 361 89 59 113 67 62 213 17 16.0% 17.3% 8.4% 17.6% 34.1% 6.7% 2019 2018 2017 2015 2009 -0.20 [-1.80, 1.40] 2008 531 Chi^a = 6.02, df = 5 (P = 0.30) effect: Z = 4.18 (P < 0.0001) Total (95% CI) -0.88 [-1.30, -0.47] Heterogeneity: Test for overall -10 -50 0 50 Favours [LEA+] Favours [LEA-] 100 D LEA. LEA Mean Differenc Mean Difference
 Mean Difference

 Weight W, Kised, 95% CI
 Year

 9.1%
 2.10 [0.78, 3.42]
 2019

 7.6%
 2.80 [1.36, 3.42]
 2019

 3.4%
 2.60 (1.91, 3.20)
 2018

 10.1%
 1.95 [0.70, 3.20]
 2015

 7.1%
 0.61 [-0.88, 2.10]
 2012

 7.1%
 0.61 [-6.85, 4.15]
 2011

 2.2%
 2.72 [1.88, 3.56]
 2009
 Study or Sul SD Total Me IV, Fi 95% CI
 Mean
 SD

 13.5
 5.9

 12.5
 5.9

 12.6
 1.6

 9.99
 4.64

 10.2
 4.7

 10.8
 6.5

 12.56
 5.55
 119 113 33 62 46 111 213
 Mean
 SD

 11.4
 5.9

 9.7
 4.3

 10
 1.5

 8.04
 3.89

 9.59
 3.4

 7.9
 3.1

 9.84
 3.77
 Ugwu, E. Jeong, E. G. Musa, I. R. Chuan, F. 217 79 49 254 116 401 361 Zubair, M Li, X. Yesil, S. Total (95% CI 697 1477 100.0% 2.42 [2.02, 2.82] Heterogeneity: Chi² = 8.01, df = 6 (P = 0.24); l² = 25% Test for overall effect: Z = 11.91 (P < 0.00001) -100 -50 0 50 Favours [LEA+] Favours [LEA-] 100

Fig 3. Meta-analysis results of the occurrence of LEA in the two groups. (A) Osteomyelitis; (B) Gangrene; (C) Body mass index; (D) WBC count.

https://doi.org/10.1371/journal.pone.0239236.g003

that osteomyelitis can increase the incidence of amputation caused by DFU (OR = 3.70, 95% CI = $3.02 \sim 4.53$, P<0.00001) (Fig 3A).

Gangrene

The data were analysed by a random-effects model to distinguish the relationship between the appearance of gangrene and amputation among DFU patients (P = 0.06, $I^2 = 60\%$). In total, 4 articles were included, and the results showed that the DFU patients with gangrene had a higher incidence of amputation (OR = 10.90, 95% CI = 5.73~20.8, P<0.00001) (Fig 3B).

Body mass index

Six studies revealed the relationship between body mass index (BMI) and amputation in DFU patients. We used a fixed-effect model for the data analysis (P = 0.30, $I^2 = 17\%$) and found that DFU-related amputations were more likely to occur in patients with a lower BMI (MD = -0.88, 95% CI = -1.30~-0.47, P<0.0001) (Fig 3C).

White blood cell count

White blood cell (WBC, 10^9 cells/L) count data from 7 papers were analysed by a fixed-effects model (P = 0.24, I² = 25%). The results of the meta-analysis revealed that there was a

А

Mean Difference	Mean Difference
ight IV, Random, 95% CI	
.8% 1.20 [-1.48, 3.88]	
-2.90 [-5.07, -0.73]	
.6% 6.00 [0.65, 11.35]	2018
.8% 1.00 [-2.83, 4.83]	
.2% 4.30 [0.09, 8.51]	
.9% 3.60 [0.42, 6.78]	
.7% 2.90 [-1.67, 7.47]	
.9% -2.00 [-4.06, 0.06]	
.3% -2.30 [-7.14, 2.54]	
.4% 3.10 [1.38, 4.82]	2009
.1% 3.20 [-1.77, 8.17]	
.7% 0.10 [-3.17, 3.37]	1998
1.24 [-0.45, 2.93]	·
%	-100 -50 0 50 100
	Favours (LEA+) Favours (LEA-)
Odds Ratio	Odds Ratio
M-H, Fixed, 95% Cl Ye	outoruno
6.91 [0.89, 53.79] 20	
0.55 [0.23, 1.31] 20	
1.22 [0.46, 3.28] 20	
0.40 [0.07, 2.25] 20	
1.46 [0.07, 31.95] 20	
0.71 [0.29, 1.75] 20	109
0.75 [0.08, 7.18] 20	
0.96 [0.61, 1.52]	T
	0.01 0.1 1 10 100
	Favours [DM2] Favours [DM1]
Ddds Ratio Random, 95% Cl Year 0.69 [0.40, 1.19] 2019	Odds Ratio M-H, Random, 95% Cl
0.47 [0.18, 1.25] 2019	
1.51 [0.87, 2.64] 2019	+
1.58 [1.02, 2.44] 2019	
1.62 [0.67, 3.94] 2018	
0.45 [0.17, 1.21] 2018	
0.54 [0.30, 0.97] 2018	
0.98 [0.41, 2.30] 2017	
3.15 [1.33, 7.46] 2017	
1.54 [0.89, 2.68] 2015	+
1.55 [0.93, 2.59] 2015	
2.10 [0.89, 4.95] 2014	+
0.94 [0.71, 1.26] 2012	+
1.10 [0.71, 1.70] 2011	
2.44 [0.70, 8.46] 2010	
1.39 [0.99, 1.96] 2009	
6.74 [0.80, 56.46] 2009	
0.94 [0.45, 1.98] 1998	
1.19 [0.96, 1.47]	•
E.	.01 0.1 1 10 100
0.	100 0.1 1 10 100 Favours [Hypertension+] Favours [Hypertension-]
Mean Difference ght IV, Fixed, 95% CI	Mean Difference Year IV, Fixed, 95% Cl
	2019
	2019
	2018
	2015
	2012
2% 0.20 [-0.36, 0.76]	2011
8% 0.90 [-0.55, 2.35]	
2% 0.10[-0.28, 0.48]	
	-100 -50 0 50 100
).	0.0% 0.07 [-0.13, 0.27]

Fig 4. Meta-analysis results of the occurrence of LEA in the two groups. (A) Age; (B) Type of diabetes; (C) Hypertension; (D) HbA1c.

significant difference between the LEA and no-LEA groups (MD = 2.42, 95% CI = $2.02 \sim 2.82$, P<0.00001) (Fig 3D).

Age

In total, 12 studies analysed the relationship between age and amputation due to DFUs. Since the data were expected to exhibit high heterogeneity, the random-effects model was suitable for the analysis (P<0.0001, $I^2 = 71\%$). The results showed no clear evidence that age is a factor that changes the incidence of amputation in DFU patients (MD = 1.24, 95% CI = -0.45~2.93, P = 0.15) (Fig 4A).

Type of diabetes

Both type 1 diabetes mellitus and type 2 diabetes mellitus can cause foot ulcers. We explored whether different types of diabetes mellitus affect the amputation incidence in DFU patients in

Risk factors Studies		Statistical model	OR/MD	95% CI	P-value	
Sex	21		1.30	1.16~1.46	< 0.00001	
Smoking history	15	Fixed-effects	1.19	1.04~1.35	0.009	
Ulcer history	6	Fixed-effects	2.48	2.00~3.07	< 0.00001	
Osteomyelitis	7	Fixed-effects	3.70	3.02~4.53	< 0.00001	
Gangrene	4	Random-effects	10.92	5.73~20.80	< 0.00001	
BMI	6	Fixed-effects	-0.88	-1.30~-0.47	< 0.0001	
WBC count	7	Fixed-effects	2.42	2.02~2.82	< 0.00001	
Age	12	Random-effects	1.24	-0.45~2.93	0.15	
Type of diabetes	7	Fixed-effects	0.96	0.61~1.52	0.86	
Hypertension	18	Random-effects	1.19	0.96~1.47	0.12	
HbA1c	8	Fixed-effects	0.07	-0.13~0.27	0.48	

Table 2. Pooled outcomes of all factors.

https://doi.org/10.1371/journal.pone.0239236.t002

this meta-analysis. Relevant data from 7 studies were analysed by a fixed-effects model (P = 0.33, $I^2 = 13\%$), and the results indicated that foot ulcers caused by different types of diabetes did not influence the amputation incidence (OR = 0.96, 95% CI = 0.61~1.52, P = 0.86) (Fig 4B).

Hypertension

In this meta-analysis, hypertension was defined as systolic blood pressure \geq 140 mmHg, diastolic blood pressure \geq 90 mmHg, or the use of antihypertensive medication. A random-effects model was used for the data analysis (P = 0.003, I² = 54%). Eighteen relevant studies were included in the analysis, and the incidence of amputation in DFU patients was not associated with hypertension (OR = 1.19, 95% CI = 0.96~1.47, P = 0.12) (Fig 4C).

HbA1c

Eight articles collected patients' HbA1c data, and these data were analysed by using a randomeffects model (P = 0.05, $I^2 = 51\%$). The analysis showed that the HbA1c level in patients with DFU does not affect the incidence of amputation (MD = 0.02, 95% CI = -0.28~0.33, P = 0.87) (Fig 4D).

The pooled outcomes of all items in our meta-analysis are shown in Table 2. We conducted a TSA of the related risk factors, including sex, smoking history, history of foot ulcers, osteomyelitis, gangrene, BMI and WBC count. The results show that the sample size of the above factors is sufficient to obtain significant results, and figures illustrating the TSA are provided in Figs 5 and 6. The horizontal red line represents the boundary at P = 0.05. A vertical horizontal line indicates the required information size. This Z-curve crosses the boundary, indicating that the sample size is adequate.

Discussion

LEA is among the most feared complications in diabetic patients. Once the first LEA occurs, up to 50% of patients require another amputation within 3–5 years [31, 32]. Numerous studies have revealed the risk factors for amputation in DFU patients, but there are still differences in some relevant factors. To determine the factors that predict the risk of LEA, we examined data from a cross-section of 21 studies conducted in 10 countries. The data included in our analysis showed very large differences in the incidence of LEA in the literature (ranging from 10.02%)




Fig 5. TSA results of the related risk factors. (A) Sex; (B) Smoking history; (C) History of foot ulcers. The information size was calculated based on relative risk reduction (RRR), alpha of 5%, power of 80%.

to 58.85%) (Table 1), and the total incidence rate was 30.84% (2006/6505). In addition, most studies (13/21) reported amputation rates greater than 25% in DFU patients.

In this meta-analysis, males exhibited a 1.30-fold increased risk of LEA compared to females, but the reason for the difference is unclear. One explanation for the correlation between the male sex and amputation incidence might be the inferior level of foot care among male patients compared to female patients as follows: men do not view their feet as often as women and may visit a physician later than women in the case of any foot problems. Women are usually more motivated to care for their health than men [33]. The literature strongly suggests that men and women differ in their responses to pain as follows: responses to pain are more variable among women than men with increased pain sensitivity and many more painful diseases commonly reported among women [34]. Furthermore, men's roles in society and family may cause them to ignore minor changes in foot lesions. Therefore, men may discover the severity of foot ulcers later than women, which may ultimately affect the outcome of DFU.

It has been widely acknowledged that smoking is a leading risk factor for peripheral arterial disease, cardiovascular disease, and total mortality in the general population [35-37]. However, the direct causal association between tobacco use and foot ulceration or amputation remains controversial [2]. The relevant studies included in this meta-analysis considered only the effects of smoking history on amputation but did not record the detailed statistics of the




Fig 6. TSA results of the related risk factors. (A) Osteomyelitis; (B) Gangrene; (C) BMI; (D) WBC count. The information size was calculated based on RRR or MD, alpha of 5%, power of 80%.

smoking frequency, amount of smoking, duration of smoking, or types of tobacco. Nevertheless, the results of this study suggest that a history of smoking is a risk factor for LEA in DFU patients; thus, DFU patients may benefit from strict smoking cessation.

A history of ulcers increases the risk of another ulcer in DFU patients [38]. Unsurprisingly, 20% to 58% of patients develop another ulcer within one year of wound healing [39]. Our study found that these recurrent foot ulcer patients ultimately had a 2.23-fold amputation rate higher than patients with first-time foot ulcers. The recurrence of foot ulcers suggests that the factors leading to foot ulcers still exist [40]. Without sustained and effective interventions, these factors may lead to the further progression of ulcers and eventually irreversible limb loss. Therefore, for patients with repeated foot ulcers, we need to identify the relevant factors that may lead to their recurrence and adopt effective measures to avoid the recurrence and progression of ulcers, which may save the patients' limbs.

BMI is a universal international standard used to measure body weight. To further explore whether obesity affects the outcome of DFU patients, we compared and analysed the

differences in BMI between amputated and nonamputated DFU patients. We found that a lower BMI resulted in a higher incidence of amputation in patients with DFU. Diabetic foot, especially those with infection, is a type of consumptive disease. Patients with a higher BMI may have a better nutritional status and, hence, more strength to cope with a severe illness [41]. The apparent protective effect of a higher BMI on the foot ulcer risk may be an instance of 'the obesity paradox', a phenomenon of better health outcomes associated with an elevated body weight [42].

The acute phase response in DFUs mostly depends on limb ischaemia, the severity of infection and the presence of osteomyelitis. Previous studies have found that leukocytosis is a poor indicator of acute osteomyelitis, and a WBC count> 12.0×10^9 cells/L is related to an increased risk of amputation [43]. Based on the data included in this study, the average WBC count in the DFU patients with amputation is close to this value (11.75×10^9 cells/L), while the WBC count in the patients who did not have amputations was only 8.83×10^9 cells/L. The difference between these two groups suggests that foot infection and the acute phase response play an important role in the progression of DFUs to amputation. Our meta-analysis also reveals that once osteomyelitis or even gangrene occurs, the risk of amputation in diabetic foot patients rapidly increases. Therefore, for DFU patients complicated with infection, especially those who progress to osteomyelitis and gangrene, adequate debridement, high-quality wound care and effective anti-infection may reduce the risk of amputation.

Diabetes has traditionally been subdivided into type 1 and type 2 diabetes. All included studies used this classification to analyse whether different types of diabetes affect amputation outcomes in DFU patients. Although there are some differences between these two types of diabetes in terms of age, aetiology and symptoms [44, 45], neither type 1 nor type 2 diabetes has been considered a risk factor for LEA in DFU. Over the past few decades, the notion of diabetes has widened with the deepening understanding of this lesion. This classification method has been considered a gross oversimplification that poorly describes the true range of diabetes [46]. However, due to the lack of relevant data, whether more detailed classification methods are related to amputation in DFU patients remains unclear.

Hypertension and diabetes mellitus are common diseases. Hypertension is twice as common in diabetics than nondiabetics [47]. In the EUROASPIRE IV survey, only 54% of diabetic patients had a blood pressure below 140/90 mmHg [48]. In this meta-analysis, approximately 65.60% of the DFU patients had concurrent hypertension (3763/5736). These data suggest that hypertension may be an important factor affecting the prognosis of DFU patients. However, after the analysis, we found that hypertension did not increase the risk of amputation in DFU patients. Nonetheless, it is still necessary for DFU patients to control their blood pressure as hypertension may lead to adverse cardiovascular and cerebrovascular events.

As a glycaemic control parameter, HbA1c showed no difference between the LEA group and the non-LEA group in this meta-analysis. A possible explanation for the current finding is that there was no significant difference in the baseline HbA1c between the amputees and nonamputees [25]. HbA1c can reflect the glycaemic control level of diabetics over the last several months, while DFUs are a long-term pathological process. After receiving recent intensive treatment, the detrimental effect of pre-existing poor diabetic control at the entry point of the study could be offset by the aggressive treatment [25]. However, previous studies have found that the benefits of glycaemic control are not evident in macrovascular outcomes [49]. Therefore, HbA1c may not be a predictor of amputation in DFU patients. Nevertheless, since the included studies were retrospective and lacked continuous data, our results cannot negate the role of glycaemic control in the prognosis of DFU patients. More prospective studies are required to confirm whether long-term glycaemic control affects the occurrence of amputation.

Limitations

There are several limitations to this study that must be considered when interpreting the results. Although the risk factors of major and minor amputations may differ, we failed to determine the risk factors of major and minor amputations separately due to the limited data in the included studies. In total, 21 papers are included in our meta-analysis, but most papers represent retrospective studies. Eight of the 21 included studies were from East Asia, which may have caused bias. Different hospitals in different regions have different diagnostic, therapeutic capabilities and medication use, which may affect the prognosis of patients. Several included studies contained significantly more patients than other studies, and these trials may lead to bias in assessing the outcome of our study. The differences in the study populations and aims of the included studies might lead to selection bias. Although some studies reported that some diabetic complications are related to DFU or amputation, due to the inconsistencies in the diagnostic criteria, we failed to analyse some other possible risk factors, such as diabetic nephropathy, diabetic retinopathy, diabetic peripheral neuropathy, coronary artery disease, peripheral arterial disease, and history of stroke. Diabetic foot is a long-term pathological process, and the included retrospective studies cannot provide longer follow-up data, which may have an impact on the results of the study.

Conclusion

In conclusion, DFU is among the most common, serious and costly complications of diabetes. Our meta-analysis identified the following significant risk factors for amputation in DFU patients: the male sex, a smoking history, a history of foot ulcers, osteomyelitis, gangrene, a lower BMI, and a higher WBC count. Once gangrene occurs, the risk of diabetic foot-related amputation rapidly increases. We also found that age, hypertension, type of diabetes, and the HbA1c level were not related to the occurrence of amputation in DFU patients. Although some risk factors are difficult to reverse, knowledge of these factors and their influence on amputation outcomes is critical for allowing multidisciplinary teams to develop management and treatment protocols for patients with DFU.

Supporting information

S1 Fig. Funnel plots. (TIF)
S1 Table. PRISMA checklist. (DOC)
S2 Table. Raw data. (XLSX)

Author Contributions

Conceptualization: Chunmei Lin, Jinhao Liu. Data curation: Chunmei Lin, Jinhao Liu, Hu Sun. Formal analysis: Chunmei Lin, Jinhao Liu. Methodology: Jinhao Liu, Hu Sun. Software: Chunmei Lin. Writing – original draft: Chunmei Lin. Writing - review & editing: Chunmei Lin, Jinhao Liu, Hu Sun.

References

- 1. Hart T, Milner R, Cifu A. Management of a Diabetic Foot. JAMA. 2017; 318(14):1387-8.
- 2. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. Jama. 2005; 293 (2):217–28. Epub 2005/01/13. https://doi.org/10.1001/jama.293.2.217 PMID: 15644549.
- Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet. 2005; 366(9498):1719–24. Epub 2005/11/18. <u>https://doi.org/10.1016/S0140-6736(05)67698-2</u> PMID: 16291066.
- Hingorani A, LaMuraglia GM, Henke P, Meissner MH, Loretz L, Zinszer KM, et al. The management of diabetic foot: A clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. Journal of vascular surgery. 2016; 63(2 Suppl):3S–21S. <u>https://doi.org/10.1016/j.jvs.2015.10.003</u> PMID: 26804367.
- Hambleton IR, Jonnalagadda R, Davis CR, Fraser HS, Chaturvedi N, Hennis AJ. All-cause mortality after diabetes-related amputation in Barbados: a prospective case-control study. Diabetes care. 2009; 32(2):306–7. https://doi.org/10.2337/dc08-1504 PMID: 18984775.
- Tseng CH, Chong CK, Tseng CP, Cheng JC, Wong MK, Tai TY. Mortality, causes of death and associated risk factors in a cohort of diabetic patients after lower-extremity amputation: a 6.5-year follow-up study in Taiwan. Atherosclerosis. 2008; 197(1):111–7. https://doi.org/10.1016/j.atherosclerosis.2007. 02.011 PMID: 17395186.
- Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010; 8(5):336–41. https://doi.org/10.1016/j. ijsu.2010.02.007 PMID: 20171303.
- Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603–5. <u>https://doi.org/10.1007/</u> s10654-010-9491-z PMID: 20652370.
- He X, Wang P, Wang Z, He X, Xu D, Wang B. Thyroid antibodies and risk of preterm delivery: a metaanalysis of prospective cohort studies. European journal of endocrinology. 2012; 167(4):455–64. https://doi.org/10.1530/EJE-12-0379 PMID: 22826476.
- Ugwu E, Adeleye O, Gezawa I, Okpe I, Enamino M, Ezeani I. Predictors of lower extremity amputation in patients with diabetic foot ulcer: findings from MEDFUN, a multi-center observational study. Journal of foot and ankle research. 2019; 12:34. Epub 2019/06/22. https://doi.org/10.1186/s13047-019-0345-y PMID: 31223342.
- Sayiner ZA, Can FI, Akarsu E. Patients' clinical charecteristics and predictors for diabetic foot amputation. Primary care diabetes. 2019; 13(3):247–51. Epub 2019/01/03. <u>https://doi.org/10.1016/j.pcd.2018</u>. 12.002 PMID: 30600172.
- Jeyaraman K, Berhane T, Hamilton M, Chandra AP, Falhammar H. Amputations in patients with diabetic foot ulcer: a retrospective study from a single centre in the Northern Territory of Australia. ANZ journal of surgery. 2019; 89(7–8):874–9. Epub 2019/07/12. <u>https://doi.org/10.1111/ans.15351</u> PMID: 31293074.
- Guo Z, Yue C, Qian Q, He H, Mo Z. Factors associated with lower-extremity amputation in patients with diabetic foot ulcers in a Chinese tertiary care hospital. International wound journal. 2019. Epub 2019/08/ 27. https://doi.org/10.1111/iwj.13190 PMID: 31448507.
- Kim SY, Kim TH, Choi JY, Kwon YJ, Choi DH, Kim KC, et al. Predictors for Amputation in Patients with Diabetic Foot Wound. Vascular specialist international. 2018; 34(4):109–16. Epub 2019/01/24. <u>https:// doi.org/10.5758/vsi.2018.34.4.109</u> PMID: 30671420.
- Musa IR, Ahmed MON, Sabir EI, Alsheneber IF, Ibrahim EME, Mohamed GB, et al. Factors associated with amputation among patients with diabetic foot ulcers in a Saudi population. BMC research notes. 2018; 11(1):260. Epub 2018/04/29. <u>https://doi.org/10.1186/s13104-018-3372-z PMID: 29703224</u>.
- Jeong EG, Cho SS, Lee SH, Lee KM, Woo SK, Kang Y, et al. Depth and combined infection is important predictor of lower extremity amputations in hospitalized diabetic foot ulcer patients. The Korean journal of internal medicine. 2018; 33(5):952–60. Epub 2017/06/13. https://doi.org/10.3904/kjim.2016.165 PMID: 28602059.
- Ferreira L, Carvalho A, Carvalho R. Short-term predictors of amputation in patients with diabetic foot ulcers. Diabetes & metabolic syndrome. 2018; 12(6):875–9. Epub 2018/05/29. <u>https://doi.org/10.1016/j.</u> dsx.2018.05.007 PMID: 29802073.

- Saleem S, Hayat N, Ahmed I, Ahmed T, Rehan AG. Risk factors associated with poor outcome in diabetic foot ulcer patients. Turkish journal of medical sciences. 2017; 47(3):826–31. Epub 2017/06/18. https://doi.org/10.3906/sag-1602-119 PMID: 28618729.
- Jeon BJ, Choi HJ, Kang JS, Tak MS, Park ES. Comparison of five systems of classification of diabetic foot ulcers and predictive factors for amputation. International wound journal. 2017; 14(3):537–45. Epub 2016/10/11. https://doi.org/10.1111/iwj.12642 PMID: 27723246.
- Jiang Y, Ran X, Jia L, Yang C, Wang P, Ma J, et al. Epidemiology of type 2 diabetic foot problems and predictive factors for amputation in China. The international journal of lower extremity wounds. 2015; 14 (1):19–27. Epub 2015/01/13. https://doi.org/10.1177/1534734614564867 PMID: 25573978.
- Chuan F, Tang K, Jiang P, Zhou B, He X. Reliability and validity of the perfusion, extent, depth, infection and sensation (PEDIS) classification system and score in patients with diabetic foot ulcer. PloS one. 2015; 10(4):e0124739. Epub 2015/04/16. https://doi.org/10.1371/journal.pone.0124739 PMID: 25875097.
- Blumberg SN, Warren SM. Disparities in initial presentation and treatment outcomes of diabetic foot ulcers in a public, private, and Veterans Administration hospital. Journal of diabetes. 2014; 6(1):68–75. Epub 2013/04/05. https://doi.org/10.1111/1753-0407.12050 PMID: 23551696.
- Zubair M, Malik A, Ahmad J. Incidence, risk factors for amputation among patients with diabetic foot ulcer in a North Indian tertiary care hospital. Foot (Edinburgh, Scotland). 2012; 22(1):24–30. Epub 2011/11/15. https://doi.org/10.1016/j.foot.2011.09.003 PMID: 22079404.
- Sun JH, Tsai JS, Huang CH, Lin CH, Yang HM, Chan YS, et al. Risk factors for lower extremity amputation in diabetic foot disease categorized by Wagner classification. Diabetes research and clinical practice. 2012; 95(3):358–63. Epub 2011/11/26. https://doi.org/10.1016/j.diabres.2011.10.034 PMID: 22115502.
- Li X, Xiao T, Wang Y, Gu H, Liu Z, Jiang Y, et al. Incidence, risk factors for amputation among patients with diabetic foot ulcer in a Chinese tertiary hospital. Diabetes research and clinical practice. 2011; 93 (1):26–30. Epub 2011/04/07. https://doi.org/10.1016/j.diabres.2011.03.014 PMID: 21466901.
- Aydin K, Isildak M, Karakaya J, Gurlek A. Change in amputation predictors in diabetic foot disease: effect of multidisciplinary approach. Endocrine. 2010; 38(1):87–92. Epub 2010/10/21. https://doi.org/10. 1007/s12020-010-9355-z PMID: 20960107.
- Yesil S, Akinci B, Yener S, Bayraktar F, Karabay O, Havitcioglu H, et al. Predictors of amputation in diabetics with foot ulcer: single center experience in a large Turkish cohort. Hormones (Athens, Greece). 2009; 8(4):286–95. Epub 2010/01/05. PMID: 20045802.
- Al-Tawfiq JA, Johndrow JA. Presentation and outcome of diabetic foot ulcers in Saudi Arabian patients. Advances in skin & wound care. 2009; 22(3):119–21. Epub 2009/02/28. <u>https://doi.org/10.1097/01</u>. ASW.0000305450.33693.f8 PMID: 19247012.
- Mehmood K, Akhtar ST, Talib A, Talib A, Abbasi B, Siraj ul S, et al. Clinical profile and management outcome of diabetic foot ulcers in a tertiary care hospital. Journal of the College of Physicians and Surgeons—Pakistan: JCPSP. 2008; 18(7):408–12. Epub 2008/09/02. 06.2008/jcpsp.408412. PMID: 18760063.
- Gurlek A, Bayraktar M, Savas C, Gedik O. Amputation rate in 147 Turkish patients with diabetic foot: the Hacettepe University Hospital experience. Experimental and clinical endocrinology & diabetes: official journal, German Society of Endocrinology [and] German Diabetes Association. 1998; 106(5):404– 9. Epub 1998/11/27. https://doi.org/10.1055/s-0029-1212006 PMID: 9831306.
- Armstrong DG, Wrobel J, Robbins JM. Guest Editorial: are diabetes-related wounds and amputations worse than cancer? International wound journal. 2007; 4(4):286–7. https://doi.org/10.1111/j.1742-481X.2007.00392.x PMID: 18154621.
- Armstrong DG, Boulton AJM, Bus SA. Diabetic Foot Ulcers and Their Recurrence. The New England journal of medicine. 2017; 376(24):2367–75. <u>https://doi.org/10.1056/NEJMra1615439</u> PMID: 28614678.
- Hamalainen H, Ronnemaa T, Halonen JP, Toikka T. Factors predicting lower extremity amputations in patients with type 1 or type 2 diabetes mellitus: a population-based 7-year follow-up study. Journal of internal medicine. 1999; 246(1):97–103. Epub 1999/08/14. https://doi.org/10.1046/j.1365-2796.1999. 00523.x PMID: 10447231.
- Keogh E. Men, masculinity, and pain. Pain. 2015; 156(12):2408–12. https://doi.org/10.1097/j.pain. 000000000000328 PMID: 26270585.
- Pan A, Wang Y, Talaei M, Hu FB. Relation of Smoking With Total Mortality and Cardiovascular Events Among Patients With Diabetes Mellitus: A Meta-Analysis and Systematic Review. Circulation. 2015; 132(19):1795–804. https://doi.org/10.1161/CIRCULATIONAHA.115.017926 PMID: 26311724.

- Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2007; 298(22):2654–64. https://doi.org/10.1001/jama. 298.22.2654 PMID: 18073361.
- Chaturvedi N, Stevens L, Fuller JH. Which features of smoking determine mortality risk in former cigarette smokers with diabetes? The World Health Organization Multinational Study Group. Diabetes care. 1997; 20(8):1266–72. PMID: 9250452.
- 38. Mishra SC, Chhatbar KC, Kashikar A, Mehndiratta A. Diabetic foot. BMJ. 2017; 359:j5064. https://doi.org/10.1136/bmj.j5064 PMID: 29146579 interests and declare the following: SM, KC, and AK were members of the guideline development group for the standard treatment guideline on the diabetic foot: prevention and management in India, 2016 published by the Ministry of Health and Family Welfare, government of India. AM provided technical input on methodology to this guideline development group.
- Uccioli L, Faglia E, Monticone G, Favales F, Durola L, Aldeghi A, et al. Manufactured shoes in the prevention of diabetic foot ulcers. Diabetes care. 1995; 18(10):1376–8. PMID: 8721941.
- 40. Wu S, Armstrong DG. Risk assessment of the diabetic foot and wound. International wound journal. 2005; 2(1):17–24. Epub 2006/05/26. https://doi.org/10.1111/j.1742-4801.2005.00085.x PMID: 16722851.
- Lin CW, Hsu BR, Tsai JS, Yang HM, Lin JR, Lin CH, et al. Effect of limb preservation status and body mass index on the survival of patients with limb-threatening diabetic foot ulcers. Journal of diabetes and its complications. 2017; 31(1):180–5. https://doi.org/10.1016/j.jdiacomp.2016.09.011 PMID: 27751708.
- Sohn MW, Budiman-Mak E, Lee TA, Oh E, Stuck RM. Significant J-shaped association between body mass index (BMI) and diabetic foot ulcers. Diabetes/metabolism research and reviews. 2011; 27 (4):402–9. https://doi.org/10.1002/dmrr.1193 PMID: 21360633.
- Pittet D, Wyssa B, Herter-Clavel C, Kursteiner K, Vaucher J, Lew PD. Outcome of diabetic foot infections treated conservatively: a retrospective cohort study with long-term follow-up. Archives of internal medicine. 1999; 159(8):851–6. PMID: 10219931.
- DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet. 2018; 391(10138):2449–62. <u>https://doi.org/10.1016/S0140-6736(18)31320-5 PMID: 29916386</u>.
- Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017; 389(10085):2239–51. https://doi. org/10.1016/S0140-6736(17)30058-2 PMID: 28190580.
- 46. Tuomi T, Santoro N, Caprio S, Cai M, Weng J, Groop L. The many faces of diabetes: a disease with increasing heterogeneity. Lancet. 2014; 383(9922):1084–94. <u>https://doi.org/10.1016/S0140-6736(13) 62219-9 PMID: 24315621.</u>
- Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes care. 2000; 23 (10):1516–26. PMID: 11023146.
- Berhan Y, Waernbaum I, Lind T, Mollsten A, Dahlquist G, Swedish Childhood Diabetes Study G. Thirty years of prospective nationwide incidence of childhood type 1 diabetes: the accelerating increase by time tends to level off in Sweden. Diabetes. 2011; 60(2):577–81. <u>https://doi.org/10.2337/db10-0813</u> PMID: 21270269.
- Orasanu G, Plutzky J. The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol. 2009; 53(5 Suppl):S35–42. https://doi.org/10.1016/j.jacc.2008.09.055 PMID: 19179216.